New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENI...( Data Presented at the American Soc...),Health

Data Presented at the American Society of Hypertension's Twenty-Third

Annual Scientific Meeting

- A cumulative forty-five percent (45%) of patients with stage 1 hypertension treated with a regimen of BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) achieved

normotension (< 120/80 mm Hg) (placebo:1.4%). - Eight out of 10 (cumulative 81%) patients with stage 1 hypertension were able to reach a goal blood pressure (BP) of < 140/90 mm Hg on BENICAR and

BENICAR HCT (placebo: 43.1%). - Six out of 10 (cumulative 60.3%) patients with stage 1 hypertension were

able to achieve a BP of < 130/80 mm Hg when treated with BENICAR and

BENICAR HCT (placebo: 6.9%).

PARSIPPANY, N.J., May 14 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that data presented at the American Society of Hypertension's Twenty-Third Annual Scientific Meeting (ASH 2008) in New Orleans demonstrates that a cumulative 45 percent of patients with stage 1 hypertension treated with a regimen of BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) were able to safely and effectively achieve a normotensive blood pressure, < 120/80 mm Hg (placebo: 1.4%). The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) defines this level as normotension.

The 15-16 week, double-blind, randomized, placebo controlled titration study conducted with 276 patients with Stage 1 and Stage 2 hypertension further demonstrated in a sub analysis that eight out of ten (cumulative 81%) patients with stage 1 hypertension were able to reduce their blood pressure to the < 140/90 mm Hg goal recommended by JNC 7 for patients (placebo: 43.1%). The study also demonstrated that six out of 10 (cumulative 60.3%) patients with stage 1 hypertension were able to reach a m
'/>"/>